Tumor-related cytokine release syndrome in a treatment-naïve patient with lung adenocarcinoma:A case report  

作　　者：Peng-Bo Deng Juan Jiang Cheng-Ping Hu Li-Ming Cao Min Li 

机构地区：[1]Department of Respiratory Medicine,National Key Clinical Specialty,Branch of National Clinical Research Center for Respiratory Diseases,Xiangya Hospital,Central South University,Changsha 410008,Hunan Province,China [2]Xiangya Lung Cancer Center,Xiangya Hospital,Central South University,Changsha 410008,Hunan Province,China [3]Center of Respiratory Medicine,Xiangya Hospital,Central South University,Changsha 410008,Hunan Province,China [4]Clinical Research Center for Respiratory Diseases in Hunan Province,Changsha 410008,Hunan Province,China [5]National Clinical Research Center for Geriatric Disorders,Xiangya Hospital,Central South University,Changsha 410008,Hunan Province,China

出　　处：《World Journal of Clinical Cases》2022年第5期1580-1585,共6页世界临床病例杂志

基　　金：Supported by National Multidisciplinary Cooperative Diagnosis and Treatment Capacity Building Project for Major Diseases(Lung Cancer);National Key R&D Program of China,No.2016YFC1303300;Xiangya Clinical Big Data Project of Central South University(Clinical big data project of lung cancer).

摘　　要：BACKGROUND Cytokine release syndrome(CRS)is defined as systemic inflammation that usually occurs following chimeric antigen receptor T-cell therapy administration;however,it has not been reported in patients with untreated non-small cell lung cancer to date.CASE SUMMARY A 44-year-old nonsmoking woman presented to the hospital due to fever,palpitation,nausea,and cough for 1 mo and was diagnosed with stage cT3N3M0(IIIc)adenocarcinoma of the lung.Auxiliary examinations revealed elevated cytokine[tumor necrosis factor-α,interleukin(IL)-1β,and IL-6]and inflammatory factor levels,which decreased after treatment with corticosteroids and immunoglobulin and when tumor growth was controlled following chemotherapy,radiotherapy,and antiangiogenesis therapy.However,tumor recurrence was observed.After administration of nivolumab as third-line treatment,the patient’s condition was transiently controlled;however,CRS-like symptoms suddenly emerged,which led to a resurgence of cytokines and inflammatory factors and rapid death.CONCLUSION CRS can develop in treatment-naïve lung cancer patients.Patients with tumorrelated CRS may be at risk of CRS recurrence,aggravation,and onset of immune checkpoint inhibitor-related adverse events.

关 键 词：Cytokine release syndrome Non-small cell lung cancer Immune checkpoint inhibitors Nivolumab Tumor necrosis factorα INTERLEUKIN-1Β INTERLEUKIN-6 Case report 

分 类 号：R734.2[医药卫生—肿瘤]